Lido Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.4M | Sell |
43,511
-10,086
| -19% | -$4.7M | 0.06% | 207 |
|
|
2025
Q4 | $22.1M | Sell |
53,597
-98
| -0.2% | -$42.2K | 0.07% | 187 |
|
|
2025
Q3 | $21M | Buy |
53,695
+7,873
| +17% | +$3.29M | 0.07% | 182 |
|
|
2025
Q2 | $20.4M | Buy |
45,822
+11,590
| +34% | +$5.34M | 0.08% | 152 |
|
|
2025
Q1 | $16.6M | Buy |
34,232
+2,626
| +8% | +$1.22M | 0.07% | 162 |
|
|
2024
Q4 | $12.7M | Buy |
31,606
+7,207
| +30% | +$3.34M | 0.06% | 189 |
|
|
2024
Q3 | $11.3M | Buy |
24,399
+335
| +1% | +$161K | 0.06% | 189 |
|
|
2024
Q2 | $11.3M | Buy |
24,064
+530
| +2% | +$230K | 0.06% | 162 |
|
|
2024
Q1 | $9.84M | Sell |
23,534
-89
| -0.4% | -$37.6K | 0.06% | 175 |
|
|
2023
Q4 | $9.61M | Sell |
23,623
-15,330
| -39% | -$5.66M | 0.06% | 164 |
|
|
2023
Q3 | $13.5M | Buy |
38,953
+21,761
| +127% | +$7.61M | 0.1% | 114 |
|
|
2023
Q2 | $6.05M | Sell |
17,192
-7,087
| -29% | -$2.39M | 0.04% | 195 |
|
|
2023
Q1 | $7.65M | Sell |
24,279
-3,953
| -14% | -$1.19M | 0.07% | 159 |
|
|
2022
Q4 | $8.15M | Buy |
28,232
+12,234
| +76% | +$3.73M | 0.1% | 115 |
|
|
2022
Q3 | $4.63M | Buy |
15,998
+11,851
| +286% | +$3.41M | 0.06% | 153 |
|
|
2022
Q2 | $1.17M | Buy |
4,147
+92
| +2% | +$24.6K | 0.02% | 312 |
|
|
2022
Q1 | $1.06M | Buy |
4,055
+712
| +21% | +$169K | 0.01% | 384 |
|
|
2021
Q4 | $734K | Buy |
3,343
+1,013
| +43% | +$197K | 0.01% | 493 |
|
|
2021
Q3 | $422K | Buy |
2,330
+295
| +14% | +$57.6K | 0.01% | 649 |
|
|
2021
Q2 | $410K | Buy |
2,035
+216
| +12% | +$45.2K | 0.01% | 601 |
|
|
2021
Q1 | $391K | Sell |
1,819
-130
| -7% | -$28.6K | 0.01% | 568 |
|
|
2020
Q4 | $460K | Buy |
1,949
+130
| +7% | +$29.8K | 0.01% | 502 |
|
|
2020
Q3 | $495K | Buy |
1,819
+211
| +13% | +$58.2K | 0.01% | 383 |
|
|
2020
Q2 | $467K | Buy |
1,608
+128
| +9% | +$34.7K | 0.01% | 360 |
|
|
2020
Q1 | $352K | Buy |
1,480
+45
| +3% | +$10.3K | 0.02% | 393 |
|
|
2019
Q4 | $314K | Buy |
1,435
+25
| +2% | +$5.06K | 0.01% | 485 |
|
|
2019
Q3 | $239K | Buy |
1,410
+15
| +1% | +$2.65K | 0.01% | 498 |
|
|
2019
Q2 | $255K | Buy |
1,395
+26
| +2% | +$4.54K | 0.01% | 457 |
|
|
2019
Q1 | $251K | Sell |
1,369
-22
| -2% | -$4.06K | 0.02% | 432 |
|
|
2018
Q4 | $230K | Buy |
1,391
+18
| +1% | +$3.12K | 0.02% | 368 |
|
|
2018
Q3 | $264K | Buy |
1,373
+49
| +4% | +$8.72K | 0.03% | 365 |
|
|
2018
Q2 | $225K | Sell |
1,324
-1,333
| -50% | -$207K | 0.03% | 373 |
|
|
2018
Q1 | $433K | Buy |
+2,657
| New | +$434K | 0.06% | 211 |
|
Other funds holding VRTX
VCM
VPM
Lido Advisors's VRTX Position: Q1 2026 in Review
Lido Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q1 2026, selling an estimated $4.7M and leaving 43,511 shares worth $19.4M. The position accounts for 0.06% of the portfolio, ranked #207.
Lido Advisors first reported a position in VRTX in Q1 2018 and has held it in 33 quarters since. The position peaked at $22.1M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Lido Advisors held 43,511 shares of Vertex Pharmaceuticals worth $19.4M as of Q1 2026.
- Lido Advisors sold 10,086 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.7M.
- Vertex Pharmaceuticals made up 0.06% of Lido Advisors's portfolio in Q1 2026, its #207 holding.
- Lido Advisors first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 33 quarters since.
- Lido Advisors's Vertex Pharmaceuticals position peaked at $22.1M in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.